Fewer Injections, Better Outcomes? The Shift Toward Longer-Lasting Anti-VEGF Treatments
.jpeg)
Intravitreal anti-VEGF injections have preserved vision for millions, but the treatment burden is real. In this NZ Optics article, Dr Francesc March de Ribot and I review how newer agents like Vabysmo and Eylea HD are extending dosing intervals, what the evidence says about switching non-responders, and where emerging therapies, i.e. gene therapy, tyrosine kinase inhibitors, sustained-delivery devices, could take us. We also cover the current state of Pharmac funding and the gaps that remain for New Zealand patients.
